Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk A/S (NYSE:NVO) today announced positive early-stage trial results for its amycretin obesity drug. The treatment, ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Stock futures are lower, looking to snap a four-day win streak but the market is still headed for its second weekly win ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram ...

Danish healthcare company Novo Nordisk A/S (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a ...

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Novo Nordisk (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical development planned.